This risk-adapted approach assumes a benefit from allogeneic HCT when at least 10% improvement could be expected in DFS compared with non-allogeneic HCT approaches. Probabilities of relapse after chemotherapy/autologous HCT were driven from previously published results.^93,94,96  Probabilities of NRM and relapse after allogeneic HCT were driven from data discussed and included in Tables, 1, 2, and 3, and these probabilities are mostly specific for RIC regimens. High-dose regimens have been less commonly used in older patients and exclusively given to those ≤65 y of age. The proposed estimates in this table could still apply to patients 60-65 y of age receiving high-dose regimens, keeping in mind that expectations for NRM would be at the higher ends of values within the range for each risk category and those for relapse would be the lower ends of values within each risk category. The estimate of DFS after allogeneic HCT was based on the combination of probabilities of relapse + NRM, whereas that after chemotherapy/autologous HCT was based on the combination of probability of relapse + 0%–5% expected probability of treatment-related mortality.

RFI indicates relapse-free interval.